Reimbursement Challenges and Solutions with Molecular Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Dr. Jorge Cortes provides examples of how personalized or precision medicine has positively impacted the approach to cancer care, citing the benefits of FLT3 inhibitors, IDH inhibitors, and MEK inhibitors, and other targeted treatments.
Dr Andrey Antov expands on how the healthcare team can work together to provide the best possible care for their patient.